Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5443_Библиотеки_им_академика_М_И_Перельмана
.pdf
12.1.2.6 Nonspecific targeting
Targeting certain cells or tissues with traditional drug delivery techniques frequently
lacks precision. Drugs administered systemically may influence both healthy and sick
tissues, causing unfavorable side effects.
12.1.2.7 Variable absorption rates
The gastrointestinal tract’s varying absorption rates present difficulties for oral deliv-
ery, a common traditional technique. The bioavailability of medications can be im-
pacted by elements like pH levels, enzymatic activity, and dietary interactions [21].
12.1.2.8 First-pass metabolism
Orally delivered medications initially travel via the liver for metabolism before enter-
ing the bloodstream. The concentration of the active medicine may be greatly de-
creased by this metabolic process, which may affect therapeutic effectiveness.
12.1.2.9 Patient adherence
Patient adherence to recommended regimens is frequently a prerequisite for tradi-
tional drug delivery . Treatment efficacy may be jeopardized by inconsistent adher-
ence, particularly in chronic illnesses requiring long-term medication [22].
Innovative solutions and future directions:
As we face the shortcomings of conventional drug delivery techniques, the pharma-
ceutical industry is being propelled into a world of game-changing opportunities by
the search for creative answers. The amalgamation of state-of-the-art technologies
and innovative methodologies establishes the foundation for tackling obstacles and
inaugurating a revolutionary epoch in precision medicine. While examining these cre-
ative fixes, we also get a sneak peek into potential future developments that could
completely transform drug delivery [23].
Nanotechnology and nanocarriers:
The application of nanotechnology to medication administration is a novel strategy.
Therapeutic substances can be precisely encapsulated, protected, and delivered with
the help of nano-sized carriers like liposomes, micelles, and polymeric nanoparticles.
These nanocarriers’ special qualities – such as their size, surface charge, and biocom-
patibility – allow them to get past biological barriers, accomplish targeted delivery,
12 Application of simulation system for selection of nanocarrier 273
https://t.me/med1917
and improve the stability of drugs. Without a doubt, the continuous investigation and
improvement of nanotechnology-based approaches holds the key to the future of
medication delivery [24].
Simulation systems and computational approaches:
Researchers have access to virtual playgrounds through simulation systems, such as
QSAR modeling, MC simulations, and MD simulations. The rational design and optimiza-
tion of delivery systems are guided by these computational tools, which provide insights
into the molecular interactions between the therapeutic medicines and nanocarriers.
The future of nanocarrier selection for a variety of medicinal payloads will be acceler-
ated by the development of simulation approaches, integration of artificial intelligence
(AI), and building of predictive models [25].
Precision medicine paradigm:
Research on medication delivery is increasingly focused on the idea of precision med-
icine, which is medicine that is customized to each patient’s unique characteristics .
Through the utilization of cutting-edge tech nologies like proteomics, metabolomics,
and genomics, scientists hope to customize medication formulations according to the
distinct genetic composition of every patient. This customized strategy may improve
therapeutic results, reduce adverse effects, and increase treatment efficacy.
Implantable and injectable devices:
Drug delivery will not be limited to traditional oral or intravenous methods in the
future. Innovative methods for the prolonged release of medicinal substances are pro-
vided by injectable and implantable devices. It is possible to program implantable de-
vices, like microchips or biodegradable implants, to deliver medications at specific
times. Controlled release is made possible by injectable depots and microneedle tech-
nologies, which eliminate the difficulties of oral administration and increase patient
compliance [26].
Bioresponsive drug delivery systems:
Drug administration now has an intelligent component thanks to the development of
bioresponsive drug delivery devices. These systems release therapeutic chemicals in
response to the body’s demands, which are triggered by particular physiological cues
or external stimuli. This novel method is best demonstrated by pH-sensitive, enzyme-
responsive, and temperature-triggered drug delivery systems, which offer improved
selectivity and regulated release patterns.
Extracellular vesicles as drug delivery vectors:
Exosomes and other extracellular vesicles are produced naturally by cells and func-
tion as nanocarriers. These vesicles have the ability to cross biological barriers and
enclose therapeutic cargo. Future studies will concentrate on improving extracellular
vesicles’ characteristics, cargo loading capacity, and targeting abilities as a means of
delivering drugs.
274 Abhishek Singh et al.
https://t.me/med1917
These cutting-edge approaches to medication delivery not only mark a break from
traditional practices but are also a step toward a time when therapeutic interventions
will be precisely personalized and optimized for maximum efficacy. The convergence
of nanotechnology, computational methods, and innovative delivery systems presents a
great opportunity for a paradigm change in drug delivery, leading to better patient out-
comes and a reorganized field of pharmaceutical sciences [27].
Nanotechnology in drug delivery:
A promising method for targeted drug delivery is provided by nanoparticles. Re-
searchers can maximize medication stability, maximize bioavailability, and facilitate
site-specific delivery while reducing off-target effects by encasing pharmaceuticals in
nanoparticles.
Implantable devices:
Drug-elut ing stents and patches are examples of implantable devices that deliver a
targeted and prolonged release of medicinal substances. These gadgets can be espe-
cially helpful in the treatment of illnesses that call for constant, long-term medication
administration.
Gene and cell therapies:
Drug delivery is changing as a result of advances in gene and cell therapies. Precision
medicine, which targets the underlying causes of diseases with little to no negative
Figure 12.1: An example of how harm was done to healthy organs or cells when conventional drugs were
supplied without the use of nanocarriers. On the other hand, new methods deliver pharmaceuticals to
targeted areas of the body using nanomedicines.
12 Application of simulation system for selection of nanocarrier 275
https://t.me/med1917
effects on healthy tissues, is made possible by customizing treatments at the genetic
and cellular levels [28].
Smart drug delivery systems:
Real-time monitoring and adaptive modifications are made possible by the integration
of sensors and response technol ogies into drug delivery devices. Dru g delivery sys-
tems with intelligence are able to adapt to changes in physiological conditions and
optimize drug release for maximum effectiveness [29].
12.1.3 Nanocarriers: a promise of precision
Nanocarriers hold the possibility of precise drug delivery and are turning into heroes
in this developing tale. These nanoscale-engineered carriers have unique characteris-
tics that make them perfect delivery systems for medicinal payloads. Liposomes, mi-
celles, and polymeric nanoparticles are examples of materials whose diversity reflects
the variety of problems that various pharmaceutical companies face. A revolution in
drug delivery technology has been brought about by the ability of nanocarriers to pre-
cisely encapsulate, preserve, and transport therapeutic molecules [30].
12.1.4 The role of simulation systems: navigating
the molecular landscape
Now enter simulation systems, an advanced toolkit that enables scientists to negotiate
the complex molecular environments controlling the interactions of biopharmaceuti-
cally difficult drugs and nanocarriers. Comprehending the molecular interactions be-
tween therapeutic drugs and their carriers is crucial in the pursuit of precision drug
delivery. These interactions are governed by a complex chemical landscape, which re-
quires advanced technologies to fully understand. In this endeavor, sim ulation sys-
tems prove to be crucial tools, providing a virtual perspective for navigating and
understanding the molecular nuances that determine the destiny of biopharmaceuti-
cally complex drugs inside the body [31].
12.2 Molecular dynamic simulations
MD simulations are at the forefront of simulation approaches. With the use of this
method, scientists may model atoms and molecules’ motions and interactions through-
out time, computationally. MD simulations allow a thorough investigation of how the
carrier’s structure changes, adapts, and interacts at the atomic and molecular levels
with the encapsulated therapeutic agent in the context of nanocarriers for drug admin-
276 Abhishek Singh et al.
https://t.me/med1917
istration. MD simulations make a substantial contribution to our understanding of the
stability, conformational changes, and binding affinities that are essential for efficient
drug delivery by offering dynamic insights [32].
12.2.1 Monte Carlo simulations
MC simulations provide a probabilistic method for modeling the thermodynamic and
kinetic parameters of molecular systems, which enhances the dynamism of MD simula-
tions. MC simulations play a key role in the field of nanocarrier selection by forecasting
the behaviors of nanocarriers in a variety of environmental scenarios. Through these
simulations, researchers may evaluate the carriers’ thermodynamic stability, forecast
their behavior in various biological environments, and optimize their performance for
certain pharmacological payloads [33].
12.2.2 Quantitative structure–activity relationship
(QSAR) modeling
QSAR modeling expands the application of simulation systems to macroscopic drug
activity, going beyond the nanoscale. With the use of this modeling approach, predic-
tions regarding the safety and effectiveness of nanocarriers are made by connecting
their physicochemical characteristics with their biological activities. When calibrated
using simulations, QSAR models seem to be highly effective instruments for the logical
creation and choice of nanocarriers that are specifically suited for biopharmaceuti-
cally demanding drugs [34].
12.2.3 Integration of experimental data
In order to verify and improve their predictions, simulation systems collaborate with
experimental data rather than working alone. The combination of empirical observa-
tions and computational insights improves the resilience of nanocarrier selection. By
connecting the virtual forecasts with actual situations and bridging the gap between
simulation and experimentation, this iterative technique enables a comprehensive
knowledge.
12.2.4 High-performance computing (HPC)
The need for processing capacity increases with simu lation complexity. As a crucial
ally, high-performance computing (HPC) speeds up simulation operations and makes
12 Application of simulation system for selection of nanocarrier 277
https://t.me/med1917
it possible to analyze big datasets. Combining simulation systems with HP C not only
makes research more efficient, but it also makes it possible to explore complex chemi-
cal landscapes at previously unattainable resolutions [35].
12.2.5 Illustrating the need for advanced solutions: case studies
in nanocarrier selection for biopharmaceutically
challenging pharmaceuticals
From real-world case studies, a captivating story unfolds as we set out to understand
the complexities of drug delivery for medications that provide biopharmaceutical
challenges. These examples not only highlight the problems with current traditional
medication delivery techniques, but they also clearly demonstrate the vital role those
cutting-edge solutions – particularly nanocarriers [36]. We learn a great deal about
the challenges that researchers encounter and the revolutionary effects of cutting-
edge methods by exploring these circumstances.
Table 12.1: The data arranged in a tabular style.
Case study Background Approach Simulation
methods
Outcomes References
Overcoming
limited
bioavailability:
the case of
paclitaxel
Paclitaxel suffers
from poor water
solubility, limiting
bioavailability.
Polymeric
nanoparticles
for paclitaxel
delivery.
Molecular dynamic
simulations
predicting
enhanced
solubility and
controlled release
kinetics.
Improved
bioavailability
and sustained
therapeutic
concentrations
[]
Targeted
delivery
precision: the
story of
liposomal
doxorubicin
Doxorubicin has
cardiotoxicity;
achieving targeted
delivery is
challenging.
Liposomes
engineered
for
doxorubicin
delivery.
Insights from
molecular dynamic
simulations
guiding enhanced
accumulation in
tumor tissues.
Reduced
cardiotoxicity,
while
maintaining
therapeutic
efficacy.
[]
Tailoring
nanocarriers
for peptide
therapeutics: a
case with
insulin
Delivery of peptides,
like insulin, faces
challenges of
enzymatic
degradation and
poor oral
bioavailability.
Tailoring
polymeric
nanoparticles
for insulin
delivery.
Integration of
molecular
dynamics and
Monte Carlo
simulations to
optimize
nanoparticle
surface properties.
Enhanced
stability and
improved
bioavailability
of insulin.
[]
278 Abhishek Singh et al.
https://t.me/med1917
12.3 Nanocarriers: types and properties
In the ever-evolving landscape of drug delivery, the advent of nanotechnology has ush-
ered in a new era of precision and efficacy. Engineered at the nanoscale, nanocarriers
are adaptable vehicles that can handle the intricacies of medications that provide bio-
pharmaceutical challenges [41]. This section provides a comprehensive overview of the
main nanocarriers, such as micelles, dendrimers, liposomes, and polymeric nanopar-
ticles, emphasizing their special qualities that make them indispensable for drug ad-
ministration [42].
12.3.1 Overview of nanocarriers
12.3.1.1 Liposomes: molecular spheres of versatility
Lipid-based vesicles, or liposomes, are among the earliest and most well researched
types of nanocarriers. Liposomes, which are made of phospholipid bilayers that
mimic natural cell membranes, provide a biocompatible and biodegradable frame-
work for the encapsulation of drugs [43]. Liposomes are highly versatile because they
can be used to encapsulate pharmaceuticals that are hydrophilic or hydrophobic in
their aqueous cores or lipid bilayers, respectively. Furthermore, because of their am-
phiphilic character, they can pass through biological barriers and deliver drugs to
particular cells or tissues with greater precision. Because of their structural flexibility,
liposomes can be tailored for co-delivery of various medicines, triggered release, or
sustained release [44].
Table 12.1 (continued)
Case study Background Approach Simulation
methods
Outcomes References
Navigating
blood–brain
barrier: a
glimpse into
CNS drug
delivery
CNS drug delivery
hindered by the
blood–brain barrier.
Designing
lipid-based
nanoparticles
for CNS drug
delivery.
Molecular dynamic
simulations
guiding
engineering of
nanocarriers with
optimal properties.
Enhanced
drug delivery
to the brain,
overcoming
the
blood–brain
barrier.
[]
12 Application of simulation system for selection of nanocarrier 279
https://t.me/med1917
12.3.1.2 Polymeric nanoparticles: tailored precision
Poly (lactic-co-glycolic acid) (PLGA) and chitosan are examples of biodegradable poly-
mers that are used to create polymeric nanoparticles, which come in a variety of
shapes and sizes. Their distinctive quality is their capacity to be precisely customized
to meet specific drug delivery needs due to their tunability in size, surface charge,
and composition [45]. Excellent stability, regulated drug release kinetics, and defense
against drug degradation are all displayed by polymeric nanoparticles. Furthermore,
their capacity to be surface-modified with ligands enables targeted distribution,
guaranteeing that the therapeutic payload is delivered precisely where it is supposed
to be [46].
12.3.1.3 Micelles: dynamic amphiphilic assemblies
Micelles are self-assembling structures made of amphiphilic molecules in aqueous sol-
utions, most commonly block copolymers or surfactants. Their unique characteristic
is the spontaneous creation of a hydrophobic core that allows hydrophobic medica-
tions to be encapsulated and encircled by a hydrophilic corona [47]. Drugs that are
poorly soluble are more stable and soluble because of this design. Micelles are natu-
rally flexible; they can be designed to release drugs in response to stimuli and can
adjust to changes in their surroundings. Their small size (usually 10–100 nm) allows
them to efficiently extravasate via leaky tumor vasculature, which makes them attrac-
tive candidates for the delivery of cancer-fighting drugs [48].
12.3.1.4 Dendrimers: branching out for controlled delivery
Dendrimers are extremely branching macromolecules with distinct structures that
frequently have a tree-like arrangement. They are able to precisely manage surface
functionality, size, and form because of their unique three-dimensional design [49].
Drugs can be conjugated to the surface of dendrimers or encapsulated in their inner
spaces, allowing for selective administration and controlled release. Additionally, be-
cause of their multivalency, which permits them to interact with biological entities,
they are appropriate for intracellular administration and diagnos tic imaging. Den-
drimers are potential prospects for applications in personalized medicine due to their
tuneable features [50].
280 Abhishek Singh et al.
https://t.me/med1917
12.3.2 Highlighting unique properties beneficial for drug delivery
12.3.2.1 Enhanced bioavailability
The carriers’ nanoscale size provides distinct pharmacokinetic benefits. By making
use of the enhanced permeability and retention (EPR) effect, nanocarriers can pas-
sively accumulate in tumor tissues when the vasculature is weakened. This mecha-
nism minimizes exposure to healthy tissues and increases medication absorption at
the target site – an important consideration in cancer therapy and other therapeutic
applications [51].
12.3.2.2 Controlled drug release
The kinetics of drug release can be highly controlled with nanocarriers. It is possible
to manipulate the characteristics of liposomes, polymeric nanoparticles, micelles, and
dendrimers to control the release of medicinal substances. When it comes to maximiz-
ing therapeutic effects, nanocarriers offer a critical level of control, whether it is
through trigger release, in response to particular environmental cues, or sustained re-
lease over an extended period of time [52].
12.3.2.3 Targeted delivery
Targeted drug delivery is made possible by surface changes of nanocarriers, which is
a crucial component for reducing side effects and improving therapeutic efficacy.
These carriers can have ligands, antibodies, or peptides attached to their surface,
which enables them to identify and bind selectively to target cell receptors. This fo-
cused strategy guarantees the accurate delivery of therapeutic payloads, which is par-
ticularly important for treating illnesses that have particular cellular targets [53].
12.3.2.4 Protection of therapeutic agents
Nanocarriers serve as barriers that prevent medications that are encapsulated from
degrading too soon. This is especially important for biopharmaceutically difficult
drugs that are vulnerable to environmental conditions or enzymatic breakdown. The
therapeutic cargo’s stability is mai ntained during its passage through biological sys-
tems thanks to its encapsulation into nanocarriers [54].
12 Application of simulation system for selection of nanocarrier 281
https://t.me/med1917
12.3.2.5 Versatility in payloads
Beyond small molecule medications, nanocarriers can carry a wide variety of thera-
peutic payloads. They have the ability to encapsulate proteins, peptides, nucleic acids,
and even imaging agents. Because of their adaptability, nanocarriers can be used to
treat a wider range of illnesses, including genetic abnormalities and cancer, which
encourages a multimodal approach to drug delivery [55].
The field of nanocarriers is broad and dynamic, providing a wide range of possi-
bilities for customized medication delivery strategies. Liposomes, polymeric nanopar-
ticles, micelles, and dendrimers are strong candidates for precision medicine because
of their inherent characteris tics [56]. Through the upcoming chapters, a more thor-
ough examination of the uses, developments, and difficulties associated with these
nanocarriers will be presented, pointing practitioners and researchers in the direc-
tion of the best approaches for drug delivery in the complex field of biopharmaceuti-
cally challenging pharmaceuticals [57].
12.4 Theoretical foundations of simulation systems
When it comes to drug delivery, the theoretical foundations of simulation systems are
essential for deciphering the complex molecular environments that control how nano-
carriers and biopharmaceutically difficult drugs interact [58]. The theoretical under-
pinnings of three well-known simulation techniques are explored in this section:
QSAR modeling, MC simulations, and MD simulation [59].
12.4.1 Molecular dynamic simulation: decoding molecular dance
MD simulations provide a special perspective for examining the intermolecular inter-
actions, conformational dynamics, and structural alterations inside nanocarriers.
These simulations are essential for comprehending how nanocarriers interact and
react with biologic al surroundings, encapsulated pharmaceut icals, and other pe rti-
nent elements in the context of drug delivery [60]. Predicting the stability of nanocar-
riers, clarifying drug loading and release mechanisms, and investigating the response
of nanoscale carriers to environmental stimuli are important applications.
12.4.1.1 Molecular dynamic simulation principles
MD simulation is a computational technique grounded in the principles of classical
mechanics. A computational method called MD simulation offers an atomistic, dy-
282 Abhishek Singh et al.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана